CSL 787
Alternative Names: CSL-787; Nebulised immunoglobulin - CSL BehringLatest Information Update: 07 Jul 2025
At a glance
- Originator CSL Behring
- Class Immunoglobulins; Serum globulins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Bronchiectasis
Most Recent Events
- 02 Jul 2025 CSL Behring plans a phase II trial for Bronchiectasis (Inhalation) in July 2025 (NCT07048262)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Bronchiectasis(Prevention) in United Kingdom (Inhalation, Aerosol)
- 27 Jul 2023 Phase-I clinical trials in Bronchiectasis (Prevention) in Germany (Inhalation) (NCT04643587)